on-interventional study observing the use of Removab for the treatment of patients with malignant ascites due to EpCAM-positive carcinomas
- Conditions
- malignant ascites
- Registration Number
- DRKS00000458
- Lead Sponsor
- Fresenius Biotech GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 159
Inclusion Criteria
Patienten mit malignem Aszites, die erstmalig mit Removab gemäß Fachinformation behandelt werden.
Patients with malignant ascites, who receive the first Removab treatment according to SmPC.
Exclusion Criteria
According to a non-interventional study, no study-related invetigatrions are required. Patients with malignant ascites, who receive the first Removab treatment accoridng to SmPC.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Puncture-free interval after the last Removab infusion<br>Quality of life of patients in terms of ascites-symptoms
- Secondary Outcome Measures
Name Time Method Verification of safety under routine conditions, characterization of patient population with regards to primary tumor and previous anti-cancer therapies, survival in post-study phase